Our Science

Adiso is a clinical stage company advancing an innovative pipeline of multimodal, locally acting small molecules aimed at modulating inflammation precisely at the site of insult.

We focus on chronic and progressive inflammatory diseases with a high unmet need for targeted therapies

Dysregulated inflammation is central to many serious diseases and current treatment paradigms are inadequate to stop disease progression. We see a significant opportunity to serve patients and the overall marketplace with our highly differentiated and locally acting therapies across a wide range of inflammatory diseases.

Our Development Pipeline

First-In-Class Small Molecule Modulator of Neutrophil Trafficking and Activation

Preclinical

IND Enabling

Phase 1

Phase 2

Phase 3

ADS051

Ulcerative Colitis

ADS051 is an oral, gut-restricted, small molecule modulator of neutrophil trafficking and activation for the treatment of ulcerative colitis. ADS051 blocks MRP2-mediated neutrophil trafficking into and FPR1-mediated neutrophil activation within the colonic lumen. Unlike currently available therapies, this addresses neutrophil-mediated tissue damage, a hallmark of UC pathology. In a healthy volunteer study and MAD patient study, ADS051 was safe and well tolerated and restricted to the gut with limited systemic exposure.

Portfolio of First-In-Class Small Molecule Inhibitors of the NLRP3 and 1 Inflammasomes

Preclinical

IND Enabling

Phase 1

Phase 2

Phase 3

ADS032

Respiratory Inflammation

ADS032 is a novel small molecule inhibitor that blocks two types of inflammasomes simultaneously, NLRP1 and NLRP3 – the innate immune system’s receptors and first line sensors of pathogens and other danger signals. Chronic activation of NLRP1 and NLPR3 is directly implicated in a wide range of inflammation-triggered conditions across multiple organ systems. By targeting both NLRP3 and NLRP1, ADS032 may provide a comprehensive anti-inflammatory approach across a range of diseases. Our development candidates are focused on Respiratory and Dermal inflammation.